Publication 2023

Bonjour à tous,
Vous trouverez ci-dessous les titres des publications des membres du réseau ENDOCAN TUTHYREF.
Félicitations aux auteurs!

Retrouvez les publications dans :   Espace membre

Références

  1. Balakirouchenane D, Seban R, Groussin L, Puszkiel A, Cottereau AS, Clerc J, Vidal M, Goldwasser F, Arrondeau J, Blanchet B, Huillard O. Pharmacokinetics/Pharmacodynamics of Dabrafenib and Trametinib for Redifferentiation and Treatment of Radioactive Iodine-Resistant Mutated Advanced Differentiated Thyroid Cancer. Thyroid. 2023 Nov;33(11):1327-1338. doi: 10.1089/thy.2023.0228. Epub 2023 Oct 12. PMID: 37725566.

  2. Baudin C, Bressand A, Buffet C, Menegaux F, Soret M, Lê AT, Cardon T, Broggio D, Bassinet C, Huet C, Armengol G, Richardson DB, Leenhardt L, Bernier MO, Lussey-Lepoutre C. Dysfunction of the Salivary and Lacrimal Glands After Radioiodine Therapy for Thyroid Cancer: Results of the START Study After 6-Months of Follow-Up. Thyroid. 2023 Sep;33(9):1100-1109. doi: 10.1089/thy.2023.0090. Epub 2023 Jun 23. PMID: 37300484.

  3. Bensiali M, Anizan N, Leboulleux S, Lamart S, Davesne E, Broggio D, Desbrée A, Franck D. Patient-specific biokinetics and hybrid 2D/3D approach integration in OEDIPE software: Application to radioiodine therapy. Phys Med. 2023 Sep;113:102462. doi: 10.1016/j.ejmp.2022.09.013. Epub 2022 Nov 21. PMID: 36424255.

  4. Blay JY, Cropet C, Mansard S, Loriot Y, De La Fouchardière C, Haroche J, Topart D, Tougeron D, You B, Italiano A, Le Brun-Ly V, Ferrero JM, Penel N, Fabbro M, Troussard X, Malka D, Ray-Coquard I, Leboulleux S, Fléchon A, Maubec E, Charles J, Dalle S, Taieb S, Garcia GCTE, Mandache AM, Colignon N, Gavrel M, Nowak F, Hoog Labouret N, Mahier Aït Oukhatar C, Gomez-Roca C. Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAFV600-mutated melanoma. ESMO Open. 2023 Nov 1;8(6):102038. doi: 10.1016/j.esmoop.2023.102038. Epub ahead of print. PMID: 37922690.

  5. Brue T, Rahabi H, Barry A, Barlier A, Bertherat J, Borson-Chazot F,Castinetti F, Cazabat L, Chabre O, Chevalier N, Christin-Maitre S, Cortet C, Drui D, Kamenicky P, Lançon C, Lioté F, Pellegrini I, Reynaud R, Salenave S, Tauveron I, Touraine P, Vantyghem MC, Vergès B, Vezzosi D, Villa C, Raverot G, Coutant R, Chanson P, Albarel F. Position statement on the diagnosis and management of acromegaly: The French National Diagnosis and Treatment Protocol (NDTP). Ann Endocrinol (Paris). 2023 Dec;84(6):697-710. doi: 10.1016/j.ando.2023.08.003. Epub 2023 Aug 12. PMID: 37579837.

  6. Castinetti F, Borson-Chazot F. Thirty Years of Progress Thanks to the RET N Engl J Med. 2023 Nov 16;389(20):1916-1918. doi: 10.1056/NEJMe2311331. Epub 2023 Oct 21. PMID: 37870964.

  7. Clement SC, Visser WE, Lebbink CA, Albano D, Claahsen-van der Grinten HL, Czarniecka A, Dias RP, Dierselhuis MP, Dzivite-Krisane I, Elisei R, Garcia- Burillo A, Izatt L, Kanaka-Gantenbein C, Krude H, Lamartina L, Lorenz K, Luster M, Navardauskaitė R, Negre Busó M, Newbold K, Peeters RP, Pellegriti G, Piccardo A, Priego AL, Redlich A, de Sanctis L, Sobrinho-Simões M, van Trotsenburg ASP, Verburg FA, Vriens M, Links TP, Ahmed SF, van Santen HM. Development of a pediatric differentiated thyroid carcinoma registry within the EuRRECa project: rationale and protocol. Endocr Connect. 2023 Feb 3;12(3):e220306. doi: 10.1530/EC-22-0306. PMID: 37931414; PMCID: PMC9986407.

  8. Cormier F, Housni S, Dumont F, Villard M, Cochand-Priollet B, Mercier-Nomé F, Perlemoine K, Bertherat J, Groussin L. NF-κB signaling activation and roles in thyroid cancers: implication of MAP3K14/NIK. Oncogenesis. 2023 Nov 16;12(1):55. doi: 10.1038/s41389-023-00496-w. PMID: 37973791; PMCID: PMC10654696.

  9. de la Fouchardière C, Fugazzola L, Locati LD, Alvarez CV, Peeters RP, Camacho P, Simon IM, Jarząb B, Netea-Maier R. Improved guidance is needed to optimize diagnostics and treatment of patients with thyroid cancer in Europe. Endocrine. 2023 Nov 25. doi: 10.1007/s12020-023-03610-5. Epub ahead of print. PMID: 38001324.

  10. Didier-Mathon H, Stoupa A, Kariyawasam D, Yde S, Cochant-Priollet B, Groussin L, Sébag F, Cagnard N, Nitschke P, Luton D, Polak M, Carré A. Borealin/CDCA8 deficiency alters thyroid development and results in papillary tumor-like structures. Front Endocrinol (Lausanne). 2023 Oct 27;14:1286747. doi: 10.3389/fendo.2023.1286747. PMID: 37964961; PMCID: PMC10641986.

  11. do Prado Padovani R, Duarte FB, Nascimento C. Current practice in intermediate risk differentiated thyroid cancer - a review. Rev Endocr Metab Disord. 2023 Nov 23. doi: 10.1007/s11154-023-09852-y. Epub ahead of print. PMID: 37995023.

  12. Ettalhaoui L, Debreuve-Théresette A, Nguyen TD, Zalzali M, Antoni D, Guilbert P. Évaluation prospective des dysthyroïdies radio-induites après irradiation mammaire et sus-claviculaire [Prospective evaluation of radiation- induced thyroid disorders after breast and supraclavicular irradiation]. Cancer Radiother. 2023 Sep;27(5):376-386. French. doi: 10.1016/j.canrad.2023.04.005. Epub 2023 May 11. PMID: 37179221.

  13. Grani G, Lamartina L, Montesano T, Maranghi M, Filetti S, Durante C, Lopatriello S. Ultrasound screening for thyroid nodules and cancer in individuals with family history of thyroid cancer: a micro-costing approach. J Endocrinol Invest. 2023 Nov;46(11):2327-2330. doi: 10.1007/s40618-023-02087-3. Epub 2023 Apr 13. PMID: 37052872.

  14. Grunenwald S, Caron P. Key data from the 2022 European Thyroid Association congress: Management of thyroid cancer with good prognosis. Ann Endocrinol (Paris). 2023 Dec;84(6):749-750. doi: 10.1016/j.ando.2023.05.004. Epub 2023 Jun 5. PMID: 37285955.

  15. Hadoux J, Elisei R, Brose MS, Hoff AO, Robinson BG, Gao M, Jarzab B, Isaev P, Kopeckova K, Wadsley J, Führer D, Keam B, Bardet S, Sherman EJ, Tahara M, Hu MI, Singh R, Lin Y, Soldatenkova V, Wright J, Lin B, Maeda P, Capdevila J, Wirth LJ; LIBRETTO-531 Trial Investigators. Phase 3 Trial of Selpercatinib in Advanced RET Mutant Medullary Thyroid Cancer. N Engl J Med. 2023 Nov 16;389(20):1851-1861. doi: 10.1056/NEJMoa2309719. Epub 2023 Oct 21. PMID: 37870969.

  16. Haissaguerre M, Caron P. Key data from the 2022 European Thyroid Association Congress. Role of molecular biology in aggressive thyroid cancer. Ann Endocrinol (Paris). 2023 Dec;84(6):746-748. doi: 10.1016/j.ando.2023.05.003. Epub 2023 Jun 3. PMID: 37277063.

  17. Jannin A, Giudici F, de la Fouchardière C, Al Ghuzlan A, Wassermann J, Chougnet CN, Drui D, Godbert Y, Ilouz F, Bardet S, Zanetta S, Roudaut N, Batisse Lignier M, Groussin L, Klein M, Zerdoud S, Lamartina L, Baudin E, Decaussin- Petrucci M, Leteurtre E, Borson Chazot F, Do Cao C, Borget I, Hadoux J; ENDOCAN- TUTHYREF Network. Factors Associated with Survival in Anaplastic Thyroid Carcinoma: A Multicenter Study from the ENDOCAN-TUTHYREF Network. Thyroid. 2023 Oct;33(10):1190-1200. doi: 10.1089/thy.2023.0164. PMID: 37855745.

  18. Lacoste-Collin L, Decaussin-Petrucci M, Buffet C. Les tests moléculaires et autres techniques ancillaires en cytologie thyroïdienne selon Bethesda 2023 [Molecular and other ancillary tests proposed by The Bethesda system for reporting thyroid cytopathology 2023]. Ann Pathol. 2023 Nov 10:S0242-6498(23)00223-7. French. doi: 10.1016/j.annpat.2023.10.004. Epub ahead of print. PMID: 37953129.

  19. Lasolle H, Schiavo A, Tourneur A, Gillotay P, de Faria da Fonseca B, Ceolin L, Monestier O, Aganahi B, Chomette L, Kizys MML, Haenebalcke L, Pieters T, Goossens S, Haigh J, Detours V, Maia ALS, Costagliola S, Romitti M. Dual targeting of MAPK and PI3K pathways unlocks redifferentiation of Braf-mutated thyroid cancer organoids. Oncogene. 2023 Nov 20. doi: 10.1038/s41388-023-02889-y. Epub ahead of print. PMID: 37985676.
  1. Leboulleux S, Benisvy D, Taieb D, Attard M, Bournaud C, Terroir-Cassou- Mounat M, Lacroix L, Anizan N, Schiazza A, Garcia ME, Ghuzlan AA, Lamartina L, Schlumberger M, Godbert Y, Borget I. MERAIODE: A Phase II Redifferentiation Trial with Trametinib and <sup>131</sup>I in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated Thyroid Cancer. 2023 Sep;33(9):1124-1129. doi: 10.1089/thy.2023.0240. Epub 2023 Jul 26. PMID: 37350119.

  2. Mavromati M, Saiji E, Demarchi MS, Lenoir V, Seipel A, Kuczma P, Jornayvaz FR, Becker M, Fernandez E, De Vito C, Triponez F, Leboulleux S. Unnecessary thyroid surgery rate for suspicious nodule in the absence of molecular testing. Eur Thyroid J. 2023 Oct 11;12(6):e230114. doi: 10.1530/ETJ-23-0114. PMID: 37855426; PMCID: PMC10620454.

  3. Moog S, Lamartina L, Bani MA, Al Ghuzlan A, Friboulet L, Italiano A, Lacroix L, Postel Vinay S, Tselikas L, Deschamps F, Bonnet B, Pani F, Baudin E, Hadoux J. Alkylating Agent-Induced High Tumor Mutational Burden in Medullary Thyroid Cancer and Response to Immune Checkpoint Inhibitors: Two Case Reports. Thyroid. 2023 Nov;33(11):1368-1373. doi: 10.1089/thy.2023.0144. Epub 2023 Oct 9. PMID: 37698883.

  4. Neyrand S, Trecourt A, Lopez J, Just PA, Descotes F, Borson-Chazot F, Ray- Coquard I, Decaussin-Petrucci M, Devouassoux-Shisheboran M. Role of gene sequencing in classifying struma ovarii: BRAF p.G469A mutation and TERT promoter alterations favour malignant struma ovarii. Histopathology. 2023 Sep 28. doi: 10.1111/his.15052. Epub ahead of print. PMID: 37771077.

  5. Prévot J, Potard G, Thuillier P, Roudaut N, Le Pennec R, Leclère JM, Mahéo C, Marianowski R, Leclère JC. Risk factors for hypothyroidism following hemithyroidectomy. Ann Endocrinol (Paris). 2023 Dec;84(6):739-745. doi: 10.1016/j.ando.2023.06.004. Epub 2023 Jul 28. PMID: 37517518.

  6. Subbiah V, Hu MI, Mansfield AS, Taylor MH, Schuler M, Zhu VW, Hadoux J, Curigliano G, Wirth L, Gainor JF, Alonso G, Adkins DR, Godbert Y, Ahn MJ, Cassier PA, Chul Cho B, Lin CC, Zalutskaya A, Barata T, Trask P, Scalori A, Bordogna W, Heinzmann S, Brose M. Pralsetinib in Patients with Advanced/metastatic RET-altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study. Thyroid. 2023 Nov 27. doi: 10.1089/thy.2023.0363. Epub ahead of print. PMID: 38009200.

  7. Van Den Heede K, Brusselaers N, Breddels E, Gaujoux S, Buffet C, Menegaux F, Chereau N. Prognostic impact of lymph node characteristics after therapeutic neck dissection for classic N1 papillary thyroid cancer. BJS Open. 2023 Nov 1;7(6):zrad124. doi: 10.1093/bjsopen/zrad124. PMID: 38016188; PMCID: PMC10684262.

  8. Xu B, Viswanathan K, Ahadi MS, Ahmadi S, Alzumaili B, Bani MA, Baudin E, Behrman DB, Capelletti M, Chau NG, Chiarucci F, Chou A, Clifton-Bligh R, Coluccelli S, de Biase D, De Leo A, Dogan S, Fagin JA, Fuchs TL, Glover AR, Hadoux J, Lacroix L, Lamartina L, Lubin DJ, Luxford C, Magliocca K, Maloberti T, Mohanty AS, Najdawi F, Nigam A, Papachristos AJ, Repaci A, Robinson B, Scoazec JY, Shi Q, Sidhu S, Solaroli E, Sywak M, Tuttle RM, Untch B, Barletta JA, Al Ghuzlan A, Gill AJ, Ghossein R, Tallini G, Ganly I. Association of the Genomic Profile of Medullary Thyroid Carcinoma with Tumor Characteristics and Clinical Outcomes in an International Multicenter Study. Thyroid. 2023 Nov 7. doi: 10.1089/thy.2023.0279. Epub ahead of print. PMID: 37842841.

  9. Žarković M, Attanasio R, Nagy EV, Negro R, Papini E, Perros P, Cohen CA, Akarsu E, Alevizaki M, Ayvaz G, Bednarczuk T, Berta E, Bodor M, Borissova AM, Boyanov M, Buffet C, Burlacu MC, Ćirić J, Díez JJ, Dobnig H, Fadeyev V, Field BCT, Fliers E, Frølich JS, Führer D, Galofré JC, Hakala T, Jiskra J, Kopp P, Krebs M, Kršek M, Kužma M, Lantz M, Lazúrová I, Leenhardt L, Luchytskiy V, McGowan A, Melo M, Metso S, Moran C, Morgunova T, Mykola T, Beleslin BN, Niculescu DA, Perić B, Planck T, Poiana C, Puga FM, Robenshtok E, Rosselet P, Ruchala M, Riis KR, Shepelkevich A, Unuane D, Vardarli I, Visser WE, Vrionidou A, Younes YR, Yurenya E, Hegedüs L. Characteristics of specialists treating hypothyroid patients: the "THESIS" collaborative. Front Endocrinol (Lausanne). 2023 Nov 7;14:1225202. doi: 10.3389/fendo.2023.1225202. PMID: 38027187; PMCID: PMC10660282.